| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/30/2005 | WO2005059643A1 Digital still camera with audio decoding and coding, a printable audio format, and method |
| 06/30/2005 | WO2005059133A2 Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent |
| 06/30/2005 | WO2005059114A1 Fat composition for promoting animal cell growth, medium for culturing animal cells containing the composition and external skin preparation |
| 06/30/2005 | WO2005059107A2 Chemokine receptor binding compounds |
| 06/30/2005 | WO2005059102A2 METHOD FOR OBTAINING AN ENRICHED POPULATION OF siRNA-EXPRESSING CELLS |
| 06/30/2005 | WO2005059098A2 Methods and compositions for treating and/or preventing neurodegenerative conditions |
| 06/30/2005 | WO2005058976A2 Low molecular polysaccharides having antithrombotic activity |
| 06/30/2005 | WO2005058966A2 Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases |
| 06/30/2005 | WO2005058951A1 Sugar chain-lacking hepatocyte growth factor |
| 06/30/2005 | WO2005058934A2 Glycosylated steroid derivatives with anti-migratory activity |
| 06/30/2005 | WO2005058932A1 Tear layer stabilizer |
| 06/30/2005 | WO2005058914A1 Crystal of oxacephem |
| 06/30/2005 | WO2005058911A2 Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
| 06/30/2005 | WO2005058908A1 SUBSTITUTED 8’-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES |
| 06/30/2005 | WO2005058898A2 Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| 06/30/2005 | WO2005058896A2 Synthesis of a polymorph of 4-amino-5-chloro-2-methoxy-n-(1-azabicyclo[3.3.1]non-4-yl)benzamide hydrochloride hydrate |
| 06/30/2005 | WO2005058895A1 Novel crystalline forms of 2, 3 dimethyl-8- (2, 6-dimethylbenzylamino) -n-hydroxyethyl-imidazo [1, 2-a] pyridine-6-carboxamide mesylate salt. |
| 06/30/2005 | WO2005058893A1 Tricyclic benzimidazoles |
| 06/30/2005 | WO2005058891A1 Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases |
| 06/30/2005 | WO2005058890A2 Hydronopol derivatives as agonists on human orl1 receptors |
| 06/30/2005 | WO2005058888A2 Oxazolidinone-quinolone hybrid antibiotics |
| 06/30/2005 | WO2005058884A2 Cyclopropane compounds and pharmaceutical use thereof |
| 06/30/2005 | WO2005058883A1 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| 06/30/2005 | WO2005058880A1 Doxepin analogs and methods of use thereof |
| 06/30/2005 | WO2005058879A1 Preventive and/or remedy for exudative otitis media |
| 06/30/2005 | WO2005058878A1 Preventive and/or remedy for dysmenorrhea |
| 06/30/2005 | WO2005058875A1 Piperazine triazine compounds, preparation thereof and pharmaceutical compositions |
| 06/30/2005 | WO2005058874A1 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication |
| 06/30/2005 | WO2005058873A1 Piperidine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication |
| 06/30/2005 | WO2005058872A1 Crystalline forms of (+)- and (-)-erythro-mefloquine hydrochloride |
| 06/30/2005 | WO2005058871A1 Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication |
| 06/30/2005 | WO2005058870A1 Amino-benzimidazoles derivatives as inhibitors of respiratory syncytial virus replication |
| 06/30/2005 | WO2005058869A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| 06/30/2005 | WO2005058867A1 Benzothiophene-and thiochromene containing phenethanolamine derivatives for the treatment of respiratory disorders |
| 06/30/2005 | WO2005058858A1 Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
| 06/30/2005 | WO2005058848A1 (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| 06/30/2005 | WO2005058847A1 Benzoxazine derivatives and uses thereof |
| 06/30/2005 | WO2005058845A2 Novel glucagon antagonists/inverse agonists |
| 06/30/2005 | WO2005058835A2 Methods of preparing aripiprazole crystalline forms |
| 06/30/2005 | WO2005058834A2 Quinolines useful in treating cardiovascular disease |
| 06/30/2005 | WO2005058829A1 Compounds for treatment of cell proliferative diseases |
| 06/30/2005 | WO2005058823A1 Urea derivative, process for producing the same, and use |
| 06/30/2005 | WO2005058822A1 Substituted amino-cycloalkanes |
| 06/30/2005 | WO2005058821A1 Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| 06/30/2005 | WO2005058819A2 Polymorphic forms of tegaserod base and salts thereof |
| 06/30/2005 | WO2005058817A1 Prolinylarylacetamides |
| 06/30/2005 | WO2005058816A1 Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours |
| 06/30/2005 | WO2005058814A2 Biocidal siloxane coating material containing n-halogenated amine and amide functional groups |
| 06/30/2005 | WO2005058808A1 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| 06/30/2005 | WO2005058800A1 Hydroxylamine derivatives |
| 06/30/2005 | WO2005058752A2 Higher fullerenes useful as radical scavengers |
| 06/30/2005 | WO2005058480A2 Particle and particle manufacturing method and apparatus |
| 06/30/2005 | WO2005058421A2 Use of a compound having two gold (i) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (i) atoms for the treatment of cancer |
| 06/30/2005 | WO2005058420A1 Combination of flupirtine and tramadol |
| 06/30/2005 | WO2005058373A2 Methods, program products, and systems for single and multi-agent dosing |
| 06/30/2005 | WO2005058367A2 Pegylated small molecules |
| 06/30/2005 | WO2005058366A2 Compositions comprising two different populations of polymer-active agent conjugates |
| 06/30/2005 | WO2005058363A2 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 06/30/2005 | WO2005058362A2 Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules |
| 06/30/2005 | WO2005058361A1 USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD |
| 06/30/2005 | WO2005058352A2 Treatment of rheumatoid arthritis with galectin-3 antagonists |
| 06/30/2005 | WO2005058348A1 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 06/30/2005 | WO2005058345A1 A treatment for necrotizing enterocolitis |
| 06/30/2005 | WO2005058341A2 Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
| 06/30/2005 | WO2005058340A1 Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
| 06/30/2005 | WO2005058331A1 Use of gallium to treat inflammatory arthritis |
| 06/30/2005 | WO2005058330A1 Phosphorus containing compounds useful for the regulation of ldl and lp(a) levels |
| 06/30/2005 | WO2005058329A1 Use of treprostinil to improve kidney functions |
| 06/30/2005 | WO2005058326A1 USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs) |
| 06/30/2005 | WO2005058324A1 Use of siramesine in the treatment of cancer |
| 06/30/2005 | WO2005058323A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 1 (mGLuR1) ANTAGONISTS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME (IBS) |
| 06/30/2005 | WO2005058322A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 1 (mGLuR1) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS |
| 06/30/2005 | WO2005058321A1 USE OF METABOTROPIC GLUTAMATE RECEPTOR 5 (mGLuR5) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS. |
| 06/30/2005 | WO2005058320A1 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF |
| 06/30/2005 | WO2005058319A1 Methods and compositions |
| 06/30/2005 | WO2005058316A1 Medicinal compositions and combinations |
| 06/30/2005 | WO2005058314A2 Methods for reducing the effects of stress on skin condition |
| 06/30/2005 | WO2005058313A1 Use of gaboxadol for treating insomnia |
| 06/30/2005 | WO2005058312A1 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof |
| 06/30/2005 | WO2005058310A2 Use of stating for the treatment of metabolic syndrome |
| 06/30/2005 | WO2005058309A1 Novel therapeutic use of indolinone derivatives |
| 06/30/2005 | WO2005058308A2 Treatment for alzheimer's disease and related conditions |
| 06/30/2005 | WO2005058307A1 Pharmaceutical compositions containing platinum complexes with secondary xanthates and therapeutic uses thereof |
| 06/30/2005 | WO2005058306A1 Glutamine-containing energy imparting amino acid composition or amino acid solution |
| 06/30/2005 | WO2005058305A1 The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases |
| 06/30/2005 | WO2005058304A1 Implantable device containing inhibitor of macrophage migration inhibitory factor |
| 06/30/2005 | WO2005058303A1 Use of treprostinil to treat and prevent ischemic lesions |
| 06/30/2005 | WO2005058302A1 Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity |
| 06/30/2005 | WO2005058301A1 Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b |
| 06/30/2005 | WO2005058300A1 Method of treating elevated plasma homocysteine levels in esrd patients |
| 06/30/2005 | WO2005058298A2 Fk228 analogs and their use as hdac-inhibitors |
| 06/30/2005 | WO2005058297A1 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |
| 06/30/2005 | WO2005058296A1 (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist |
| 06/30/2005 | WO2005058295A2 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 06/30/2005 | WO2005058294A1 Copper antagonist compounds |
| 06/30/2005 | WO2005058293A1 Use of memantine for the treatment of proliferative retinal diseases |
| 06/30/2005 | WO2005058292A1 New use in gastrointestinal disorders |
| 06/30/2005 | WO2005058291A1 Microemulsion preconcentrate comprising a renin inhibitor |
| 06/30/2005 | WO2005058290A2 Vitamin e for facilitating the synchronization of circadian rhythm |
| 06/30/2005 | WO2005058287A2 Transdermal delivery system of hormones without penetration enhancers |